COMPARISON OF SERUM BONE TURNOVER MARKERS AND PAIN SCORES IN BONE METASTASES DUE TO HORMONE-REFRACTORY PROSTATE CANCER (HRPCA): EFFECTS OF COMBINED AND REPEATED ZOLEDRONIC ACID AND DOCETAXEL-BASED CHEMOTHERAPY

2006 ◽  
Vol 5 (2) ◽  
pp. 55 ◽  
Author(s):  
A. Hegele ◽  
H.G. Wahl ◽  
A.J. Schrader ◽  
S. Sevinc ◽  
L. Koliva ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Bone Turnover Markers ◽  
Hormone Refractory Prostate Cancer ◽  
Pain Scores ◽  
Hormone Refractory ◽  
Turnover Markers

1016: Randomized Trial of Denosumab Versus Zoledronic Acid in Prostate Cancer Patients with Bone Metastases and Elevated Bone Turnover Markers After Receiving Zoledronic Acid Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 335-336
Author(s):  
Linda Bosserman ◽  
Karim Fizazi ◽  
Allan Lipton ◽  
Yasmin Rahim ◽  
Tirzo Suarez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Bone Turnover Markers ◽  
Acid Therapy ◽  
Turnover Markers

Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases

2009 ◽  
Vol 37 (1) ◽  
pp. 103-113 ◽  
Author(s):  
Athanasios Zafeirakis ◽  
Georgios Papatheodorou ◽  
Athanasios Arhontakis ◽  
Athanasios Gouliamos ◽  
Lambros Vlahos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Turnover ◽  
Cancer Patients ◽  
Bone Turnover Markers ◽  
Palliative Treatment ◽  
Hormone Refractory Prostate Cancer ◽  
Osseous Metastases ◽  
Hormone Refractory ◽  
Turnover Markers

Bone Turnover Markers as Predictors of Mortality Risk in Prostate Cancer Patients with Bone Metastases Following Treatment with Zoledronic Acid

2011 ◽  
Vol 59 (4) ◽  
pp. 604-612 ◽  
Author(s):  
Klaus Jung ◽  
Kurt Miller ◽  
Manfred Wirth ◽  
Michael Albrecht ◽  
Michael Lein
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Mortality Risk ◽  
Bone Turnover Markers ◽  
Predictors Of Mortality ◽  
Turnover Markers

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

Cancer ◽  
2007 ◽  
Vol 109 (6) ◽  
pp. 1090-1096 ◽  
Author(s):  
William K. Oh ◽  
Kevin Proctor ◽  
Mari Nakabayashi ◽  
Carolyn Evan ◽  
Lauren K. Tormey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Renal Impairment ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

MER-101–03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5161-5161
Author(s):  
C. McHugh ◽  
K. Madigan ◽  
A. Walsh ◽  
J. Fox ◽  
T. W. Leonard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Phase Ii ◽  
Performance Status ◽  
Hormone Refractory Prostate Cancer ◽  
Open Label ◽  
Secondary Endpoints ◽  
Hormone Refractory

5161 Background: The primary objective of this study is to examine the pharmacodynamic effects of two different regimens of zoledronic acid, Orazol 20 mg tablets versus Zometa 4mg IV infusion once-monthly therapy on biomarkers in male bisphosphonate-naïve hormone-refractory prostate cancer patients. Methods: The study is an open-label, multi-center phase II clinical trial to compare oral Orazol 20 mg tablets weekly, to infusions of intravenous Zometa 4mg monthly, in males with hormone-refractory prostate cancer, bone metastases, and no prior bisphosphonate treatment. Patients were assigned into one of three cohorts. The three treatments administered were IV Zometa, 4 mg, 15 minute infusion, Day 0 and Day 28; Orazol po, 20 mg, Days 0, 7, 14, 21, 28, 35, 42, and 49; and Orazol po, 20 mg, Days 0, 1, 2, 3, 28, 35, 42, and 49. The study population consisted of men with hormone refractory prostate cancer as evidenced by history of rising PSA levels (last 2 of 3 PSA levels must be above nadir), who are bisphosphonate-naive, and have radiographically-confirmed bone metastases. Efficacy assessments: The primary endpoints are the assessment of response of four biomarkers, urinary NTX, serum CTX, serum bone specific alkaline phosphatase, and serum calcium on days -7, 0, 7, 14, 21, 28, 35, 42, 49, and 56. Secondary endpoints are assessments of performance and pain scores based on ECOG performance status, BPI, and analgesic use. Safety assessments include physical examinations, vital signs and body weight, hematology panel, urinalysis, and blood chemistry panel. Results: The results demonstrated a rapid decrease for all four biomarkers. This decrease was seen at seven days, and was sustained throughout the study. There were no statistically significant differences between any of the treatments in the primary and secondary endpoints. Conclusions: From the results of MER-101–03, Orazol weekly therapy appears to be as effective as Zometa, based on the biomarkers analyzed. Orazol offers a substantial improvement in therapy over IV infusion for patients, with efficacy that is at least comparable based on the results obtained here. No significant financial relationships to disclose.

Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid

The Prostate ◽  
2009 ◽  
Vol 69 (6) ◽  
pp. 624-632 ◽  
Author(s):  
Michael Lein ◽  
Kurt Miller ◽  
Manfred Wirth ◽  
Lothar Weißbach ◽  
Christoph May ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Metastatic Prostate Cancer ◽  
Predictive Tools ◽  
Skeletal Complications ◽  
Turnover Markers
Sign in / Sign up

Export Citation Format

Share Document